84 results on '"Maurillo, Luca"'
Search Results
2. Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia
3. The Added Value of Multi-State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis
4. Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases
5. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
6. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
7. Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia
8. Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol
9. Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)
10. Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients
11. Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience
12. Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia
13. Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement
14. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
15. Unravelling Genetic Mechanisms of Erythrocytosis: A Real-Life Experience from a Single Center
16. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
17. Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN
18. Low Bax/Bcl-2 Ratio and NOTCH1 Mutations Represent Powerful and Synergistic Adverse Prognostic Factors within Trisomy 12 Chronic Lymphocytic Leukemia (CLL)
19. Pattern of Central Nervous System (CNS) Involvement in Adult Acute Myeloid Leukemia (AML) and Its Impact on Outcome
20. Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score
21. MEN1112/OBT357, an Anti Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Autologous Ex Vivo Assay: A Potential New Targeted Therapy for AML
22. Cost Description on a Cohort of 659 Patients with Adult MDS Included into the Italian Lazio Region Registry (the GROM-L)
23. Variable Outcome of Allogeneic Stem Cell Transplant According to the Different Levels of Pre-Transplant Minimal Residual Disease, in Adult Patients with Acute Myeloid Leukemia
24. Clinical Significance of Apoptosis in Chronic Lymphocytic Leukemia (CLL)
25. Allogeneic but Not Autologous Stem Cell Transplant Attenuates the Negative Prognostic Impact Dictated By Pretransplant MRD Positivity
26. Bendamustine Improves Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) According to Different Clinical and Biological Prognostic Factors
27. Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry
28. Targeting and Depletion of Acute Myeloid Leukemia Blasts By MEN1112, a Novel Humanized Defucosylated Monoclonal Antibodies with Specificity for Bst1/CD157 Antigen
29. Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials
30. Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias
31. Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile
32. Age-Stratified Analysis Of The Prognostic Role Of Minimal Residual Disease Detection By Flow Cytometry, In Adult Patients With Acute Myeloid Leukemia
33. Genomic Aberrations Dramatically Improve The Strong Prognostic Impact Of IGHV Mutational Status In Chronic Lymphocytic Leukemia (CLL)
34. Clinical Significance of 13q14 Number of Deleted Cells in Chronic Lymphocytic Leukemia
35. Risk-Adapted, MRD-Refined Therapeutic Approach for the Treatment of Acute Myeloid Leukemia: From a Single Center Experience to the Cooperative Gimema Protocol AML1310
36. Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience
37. Intensive Chemotherapy Does Not Prolong Survival Compared to 5-Azacitidine in Patients Aged 70 Years or More with Untreated Acute Myeloid Leukemia
38. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
39. Immunotherapeutic Maintenance Strategy Prolongs Response Duration and Overall Survival Preventing Relapse in Chronic Lymphocytic Leukemia (CLL),
40. Clinical Monoclonal B Cell Lymphocytosis Is a Strong Favorable Prognosticator Independent From Biological and Clinical Parameters,
41. MRD-Directed Post-Remissional Therapy Dramatically Improves Outcome of Adult Patients with High Risk AML by Implementing Allogeneic Transplant Option
42. Phase II Study of Bortezomib as a Single Agent In Patients with Relapsed/Refractory or De Novo Acute Myeloid Leukemia Unfit for Intensive Therapy
43. Clinical Significance of CD69 Expression In Chronic Lymphocytic Leukemia
44. Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia
45. Rituximab Maintenance Following Chemoimmunotherapy Improves Outcome in B-Cell Chronic Lymphocytic Leukemia.
46. In Acute Myeloid Leukemia, the Use in Induction of Standard Dose Arac Is Associated with a Better Quality of Response as Compared to An Induction Regimen Containing High Dose Arac.
47. The Earliest Activation Marker CD69 Is An Independent and Strong Progression Indicator in B-Cell Chronic Lymphocytic Leukemia.
48. The Amount of Spontaneous Apoptosis Is An Independent Strong Disease Progression Indicator in B-Cell Chronic Lymphocytic Leukemia (B-CLL)
49. High CD79b Expression Predicts a Poor Outcome in B-Cell Chronic Lymphocytic Leukemia (B-CLL).
50. The Amount of Mitochondrial Apoptosis Exerts Prognostic Impact on Normal Karyotype Acute Myeloid Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.